UMIN ID: UMIN000001633
Registered date:14/01/2009
Vaccination trial with the PBF-derived peptide in HLA-A24+ patients with osteosarcoma
Basic Information
| Recruitment status | Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | Osteosarcoma |
| Date of first enrollment | 2009/01/01 |
| Target sample size | 18 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | HLA-A24-restricted PBF peptide (AYRPVSRNI) 1mg + IFA HLA-A24-restricted PBF peptide 10mg + IFA HLA-A24-restricted PBF peptide 1mg + IFA + Interferon alpha |
Outcome(s)
| Primary Outcome | Toxicity, immunological response and anti-tumor effects |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 10years-old |
|---|---|
| Age maximum | 70years-old |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Exclusion criteria included (i) prior chemotherapy, steroid therapy, or other immunotherapy within the past 4 weeks, (ii) presence of severe organ failure or other cancers that might influence the prognosis, (iii) immunodeficiency or a history of splenectomy, (iv) severe cardiac insufficiency, acute infection, or hematopoietic failure, (v) pregnany or ongoing breast-feeding, (vi) unsuitability for the trial based on the clinical judgment of the doctors involved. |
Related Information
| Primary Sponsor | Dept Orthopaedic Surgery, Sapporo Medical University |
|---|---|
| Secondary Sponsor | Dept Pathology, Sapporo Medical University |
| Source(s) of Monetary Support | Grants-in-Aid from MEXT, the Ministry of Health, Labor and Welfare. |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Takuro Wada |
| Address | Japan |
| Telephone | |
| twada@sapmed.ac.jp | |
| Affiliation | Sapporo Medical University Department of Orthopaedic Surgery |
| scientific contact | |
| Name | Takuro Wada |
| Address | South-1, West-16, Chuo-ku, Sapporo Japan |
| Telephone | |
| Affiliation | Sapporo Medical University Department of Orthopaedic Surgery |